Evidence map›Paper›PMID 30429257›Full record

ArticleJournal of clinical microbiology2019

MODS-Wayne, a Colorimetric Adaptation of the Microscopic-Observation Drug Susceptibility (MODS) Assay for Detection of

Roberto Alcántara, Patricia Fuentes, Ricardo Antiparra, Marco Santos, Robert H Gilman, Daniela E Kirwan, Mirko Zimic, Patricia Sheen

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A simplified pyrazinamidase test forJournal of clinical microbiology · 2024
    Article
  4. Article
  5. QuantitativeJournal of clinical microbiology · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Roberto AlcántaraLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Patricia FuentesLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Ricardo AntiparraLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Marco SantosLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Robert H GilmanDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Daniela E KirwanInstitute for Infection and Immunity, St. George's, University of London, London, United Kingdom.
Mirko ZimicLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Patricia SheenLaboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru patricia.sheen@upch.pe.
Universidad Peruana Cayetano Heredia · PEJohns Hopkins University · USSt George's, University of London · GB

Funding

Medical Research Council MR/P019978/1Medical Research Council MR/P019978/2Wellcome TrustWellcome Trust 099805/Z/12/Z
6 · The paper itself

Abstract

Although pyrazinamide (PZA) is a key component of first- and second-line tuberculosis treatment regimens, there is no gold standard to determine PZA resistance. Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% of extensively drug-resistant tuberculosis (XDR-TB) strains are also PZA resistant.

Indexed as

Drug Resistance, BacterialAdolescentAdultAgedAged, 80 and overAntitubercular AgentsColorimetryFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPyrazinamideSensitivity and SpecificitySputumAntitubercular AgentsPyrazinamideMODSpyrazinamidepyrazinoic acidsputumtuberculosis

Identifiers

PMID30429257
PMCPMC6355525
OpenAlexW2900806040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.